Why Novo Nordisk surged 14% on new weight-loss drug results
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...
Investor's Business Daily on MSN2h
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
Novo Nordisk stock surges on trial results for injectable GLP-1
Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin. Yahoo ...
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...